EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth 26.04.2024 / 11:55 CET/CEST The issuer is solely responsible for the content of this announcement. CHEPLAPHARM CLOSES FINANCIAL YEAR 2023 WITH RECORD REVENUE AND DOUBLE-DIGIT GROWTH Greifswald, 26th April 2024 Double-digit revenue growth again: +17% YoY to € 1,498.4 million (FY2022: € 1,279.5 million) EBITDA increases significantly by +14% YoY to € 780.5 million (FY2022: € 685.7 million) EBITDA margin remains at a high and industry-leading ..read more

M1 Kliniken AG / Key word(s): Share Buyback M1 Kliniken AG decides to start share buyback 26-Apr-2024 / 11:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014   M1 Kliniken AG decides to start share buyback Berlin, 26.04.2024 – The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,000,000 shares of th ..read more

Kinarus Therapeutics Holding AG / Key word(s): Acquisition/Corporate Action 26-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR   The Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) with Curatis AG and related transactions were completed on 25 April 2024 The first trading day of the combined entities, Curatis Group (CURN.SW), is today, 26 April 2024 A total of CHF4.36m in cash was raised in Q ..read more

EQS-News: STRATEC SE / Key word(s): Quarter Results STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2024 26.04.2024 / 06:55 CET/CEST The issuer is solely responsible for the content of this announcement. STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2024 Subdued start to financial year as expected, but noticeable revival apparent in market and very strong sales growth expected for second quarter of 2024 Consolidated sales Q1/2024 -15.7% at constant currency to € 50.9 million (Q1/2023: € 60.5 million) Efficiency measures and structural changes taking effect: Despite negative sc ..read more

EQS-News: SYNBIOTIC SE / Key word(s): Financing 1.6 million euros for Hanf Farm: Federal Ministry for Economic Affairs and Climate Protection funds bio-economy project (news with additional features) 25.04.2024 / 12:33 CET/CEST The issuer is solely responsible for the content of this announcement. The Federal Ministry for Economic Affairs and Climate Protection (BMWK) is funding a Hanf Farm project in the field of industrial bio-economy with 1.6 million euros. The official funding decision has now been handed over to Managing Director Rafael Dulon and Project Manager Michael Bieder by State ..read more

EQS-News: MPH Health Care AG / Key word(s): Preliminary Results/Annual Results MPH Health Care AG: Preliminary IFRS result 2023 Equity increases by almost 30 million euros to 251.0 million euros, which corresponds to 58.62 euros per share. EBIT increases to 30.2 million euros. 25.04.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. MPH Health Care AG: Preliminary IFRS result 2023 Equity (net asset value) increases by almost 30 million euros to 251.0 million euros, which corresponds to 58.62 euros per share. EBIT increases to 30.2 million euros. Th ..read more

EQS-News: Marinomed Biotech AG / Key word(s): Alliance Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios 25.04.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed will apply the Marinosolv solubilization technology to improve target compounds with the goal of developing products with differentiated pharmacological profiles The project covers the proof-of-concept eva ..read more

EQS-News: Drägerwerk AG & Co. KGaA / Key word(s): Quarter Results/Forecast Drägerwerk AG & Co. KGaA: Dräger with solid business performance in the first quarter of 2024 25.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dräger with solid business performance in the first quarter of 2024 Order intake slightly above high prior-year level Net sales and earnings below strong prior-year quarter due to base effects Annual forecast confirmed Lübeck – Drägerwerk AG & Co. KGaA increased its order intake in the first quarter of 2024 thank ..read more

EQS-News: Formycon AG / Key word(s): Annual Report/Forecast Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance 25.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Press release // April 25, 2024 Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance Preliminary results 2023 confirmed Group revenue increases by 83% compared to the previous year to a total of € 77.7 million Positiv ..read more

EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 25.04.2024 / 07:21 CET/CEST The issuer is solely responsible for the content of this announcement. Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix to HealthCare Royalty finances furth ..read more